Results 211 to 220 of about 99,760 (276)

Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma. [PDF]

Cureus
Tai W, Kim D, Dib J, Thomas J, Gopishetty S, Idogun P, Anyadibe A, Ayetoran A, Zaidi S, Balaraman S, Jaiyesimi I.   +10 more
europepmc   +1 more source

Clinical Utility of Multiplex Ligation-Dependent Probe Amplification in the Genetic Assessment of Patients with Myelodysplastic Syndrome. [PDF]

Biomedicines
Valeva R, Levkova M, Yahya D, Hachmeriyan M, Micheva I.   +4 more
europepmc   +1 more source

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. [PDF]

Blood Adv
Cortes JE, Yang J, Roboz GJ, Dinner SN, Wang ES, Wei AH, Tian H, di Trapani F, Baer MR, Donnellan W, Watts JM.   +10 more
europepmc   +1 more source

FDA approval of imetelstat: a new era in the treatment of lower-risk myelodysplastic syndrome. [PDF]

Ann Med Surg (Lond)
Shahnoor S, Raza IF, Rashid M, Panhwar H, Fatima I, Gul S, Nadeem K, Khan S, Mahmmoud Fadelallah Eljack M.   +8 more
europepmc   +1 more source

Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer Centers. [PDF]

Adv Hematol
Willis C, Hejazi A, Williams VL, Comperatore C, Tantravahi S, Ali NA, Gilreath J, Kovacsovics T, Au T, Tan M, Brendle M, Komrokji R, Yoo M, Ashraf M, Khakwani A, Iorga ŞR, Sadek I, Sallman DA, Stenehjem D.   +18 more
europepmc   +1 more source

Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome. [PDF]

Front Immunol
Le M, Dong N, Tan Z, Ye B, Chen J, Liu S.   +5 more
europepmc   +1 more source

Oral Squamous Cell Carcinoma in a Patient with Myelodysplastic Syndrome: Report of a Case and Literature Review. [PDF]

Front Dent
Omidsalar P, Moradzadeh Khiavi M, Sheykhbahaei N.   +2 more
europepmc   +1 more source

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents. [PDF]

Ther Adv Hematol
Zeidan AM, Zhao R, Tepsick JG, Lan Z, Salimi T.   +4 more
europepmc   +1 more source

Frontline treatment of IDH1-mutated myelodysplastic syndrome with ivosidenib: clinical cases and therapeutic insights. [PDF]

Ther Adv Hematol
Antonios B, Dutton N, Fazal S.
europepmc   +1 more source